Showing results (331-340 of 384) with videos related to
Sort By:
Pageof 39
JAMA Oncology|November 2, 2018
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical TrialLillian L Siu, Caroline Even, Ricard Mesía, et al.Nutrition and Cancer|March 14, 2019
Soy Isoflavone Supplementation Increases Long Interspersed Nucleotide Element-1 (LINE-1) Methylation in Head and Neck Squamous Cell CarcinomaLaura S Rozek, Shama Virani, Emily L Bellile, et al.The Oncologist|May 31, 2022
Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141Maura L Gillison, George Blumenschein, Jerome Fayette, et al.Targeted Oncology|October 24, 2023
A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaAlbiruni R Abdul Razak, Hung-Ming Wang, Jang-Yang Chang, et al.Head & Neck|December 22, 2022
Ninety-day mortality following transoral robotic surgery or radiation at Commission on Cancer-accredited facilitiesJames R Janopaul-Naylor, Manali Rupji, Rachel A Tobillo, et al.Oral Oncology|June 10, 2018
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expressionRobert L Ferris, George Blumenschein, Jerome Fayette, et al.Biomedicines|August 26, 2023
Survival Outcomes in T3 Laryngeal Cancers: Primary Total Laryngectomy vs. Concurrent Chemoradiation or Radiation Therapy-A Meta-AnalysisKarthik Nagaraja Rao, Prathamesh S Pai, Prajwal Dange, et al.International Journal of Radiation Oncology, Biology, Physics|November 21, 2022
Outcomes Stratification of Head and Neck Cancer Using Pre- and Post-treatment DNA Methylation From Peripheral BloodDavid C Qian, Bryan C Ulrich, Gang Peng, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2021
Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311)Robert L Ferris, Yael Flamand, Gregory S Weinstein, et al.The Oncologist|June 6, 2018
CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck CancerMaura L Gillison, George Blumenschein, Jerome Fayette, et al.Pageof 39